non-small cell

• 非小細胞

関

NSC

WordNet

1. used to express refusal or denial or disagreement etc or especially to emphasize a negative statement; "no, you are wrong"
2. a negative; "his no was loud and clear"
3. referring to the degree to which a certain quality is present; "he was no heavier than a child" (同)no more
4. not in any degree or manner; not at all; "he is no better today"
5. quantifier; used with either mass nouns or plural count nouns for indicating a complete or almost complete lack or zero quantity of; "we have no bananas"; "no eggs left and no money to buy any"; "have you no decency?"; "did it with no help"; "Ill get you there in no time"
6. slight or limited; especially in degree or intensity or scope; "a series of death struggles with small time in between"
7. a garment size for a small person
8. the slender part of the back
9. limited or below average in number or quantity or magnitude or extent; "a little dining room"; "a little house"; "a small car"; "a little (or small) group" (同)little
10. have fine or very small constituent particles; "a small misty rain"
11. on a small scale; "think small"
12. small room in which a monk or nun lives (同)cubicle
13. a device that delivers an electric current as the result of a chemical reaction (同)electric cell
14. a room where a prisoner is kept (同)jail cell, prison cell
15. (biology) the basic structural and functional unit of all organisms; they may exist as independent units of life (as in monads) or may form colonies or tissues as in higher plants and animals
16. any small compartment; "the cells of a honeycomb"
17. a small unit serving as part of or as the nucleus of a larger political movement (同)cadre
18. the fifth of the seven canonical hours; about 3 p.m.

PrepTutorEJDIC

1. National Security Council(米国の)国家安全保障会議
2. 《名詞の前に置いて》『一つも』(『一人も,少しも』)・・・『ない』 / 《補語につけて》『決して・・・でない』 / 《省略文で》・・・なし;・・・お断り / 《話》少ししか(あまり)・・・ない / (肯定の問いに対して)『いいえ』;(否定の問いに対して)はい,ええ / 《not, norの前に挿入して》『いや』,否 / 《形容詞の前に置その形容詞を否定して》…どころではない / 《比較級の前に置いて》ちっとも…でない,…と全く同じ / 《… or no の形で》…であってもなくても / 《驚き・困惑・不信などを表して》とんでもない / 《単数形で》『拒否』,「『いいえ』」という返事 / 《複数形で》反対[投]票
3. (大きさが)『小さい』,小形の;(量が)『少ない』,わずかな / 『取るに足りない』,ささいな(trivial) / 《名詞の前にのみ用いて》(仕事・活動などが)『小規模の』,ささやかな / 心が狭い,利己的な / (音・声が)弱い,小さい / (文字が)小型の,小文字の / 《the~》小さいもの;(…の)細い部分《+『of』+『名』》 / 《複数形で》《英》(衣類・ハンカチなどの)小物,小間物 / 小さく,細かく / (声などが)低く,弱く / 小規模に,こぢんまりと
4. (刑務所の)『独房』;(修道院の)小さい独居室 / (ミツバチの)みつ房,巣穴 / 小さい部屋 / 『細胞』 / 電池 / 花粉室 / (共産党などの)細胞

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 進行非小細胞肺癌の治療の役割 overview of the treatment of advanced non small cell lung cancer
• 2. 肺癌が疑われる患者の初期評価、診断、および病期分類の概要 overview of the initial evaluation diagnosis and staging of patients with suspected lung cancer
• 3. 非小細胞肺癌の治療プロトコル treatment protocols for non small cell lung cancer
• 4. 上皮成長因子受容体変異を有する進行非小細胞肺癌に対する全身療法 systemic therapy for advanced non small cell lung cancer with an activating mutation in the epidermal growth factor receptor
• 5. Immunotherapy of non-small cell lung cancer with immune checkpoint inhibition

English Journal

• Immunohistochemical study of cyclooxygenase-2 in skin tumors.

• Amirnia M1, Babaie-Ghazani A, Fakhrjou A, Khodaeiani E, Alikhah H, Naghavi-behzad M, Zarrintan A.Author information 1Department of Dermatology, Sina Hospital, Tabriz University of Medical Sciences , Tabriz , Iran.AbstractINTRODUCTION: Anti-cancerous effects of cyclooxygenase-2 (COX-2) inhibitors have been reported in different cancers. High expression of COX-2 has been demonstrated in various neoplasms such as colorectal, gastric, esophageal, breast, non-small cell lung cancers, and pre-neoplastic lesions such as colorectal adenomas and Barrett's esophagus.
• The Journal of dermatological treatment.J Dermatolog Treat.2014 Oct;25(5):380-7. doi: 10.3109/09546634.2012.674191. Epub 2012 Jun 5.
• INTRODUCTION: Anti-cancerous effects of cyclooxygenase-2 (COX-2) inhibitors have been reported in different cancers. High expression of COX-2 has been demonstrated in various neoplasms such as colorectal, gastric, esophageal, breast, non-small cell lung cancers, and pre-neoplastic lesions such as co
• PMID 22667343

• MicroRNA-198 Inhibits Proliferation and Induces Apoptosis of Lung Cancer Cells Via Targeting FGFR1.

• Yang J1, Zhao H, Xin Y, Fan L.Author information 1Thoracic Department, Shanghai Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai, 200030, China.AbstractLung cancer is the most common cause of death from cancer worldwide and recent studies have revealed that microRNAs play critical roles to regulate lung carcinogenesis. Here we present evidence to show the role of miR-198 in lung cancer development. Our results showed that ectopic expression of miR-198 inhibits the viability and induces the apoptosis of human non-small cell lung cancer cells A549 and NCI-H460, while miR-198 inhibition resulted in opposite changes. In nude mice miR-198 inhibits A549 growth of tumor graft. We further demonstrated that miR-198 directly targets fibroblast growth factor receptor 1 (FGFR1) in lung cancer cells. Restoring FGFR1 expression blocked the inhibitory function of miR-198, while FGFR1 inhibition achieved the similar phenotypes of miR-198 overexpression. Hence, our data delineates the molecular pathway by which miR-198 inhibits lung cancer cellular proliferation and induces apoptosis, and may have important implication for the treatment of lung carcinogenesis. J. Cell. Biochem. 115: 987-995, 2014. © 2013 Wiley Periodicals, Inc.
• Journal of cellular biochemistry.J Cell Biochem.2014 May;115(5):987-95. doi: 10.1002/jcb.24742.
• Lung cancer is the most common cause of death from cancer worldwide and recent studies have revealed that microRNAs play critical roles to regulate lung carcinogenesis. Here we present evidence to show the role of miR-198 in lung cancer development. Our results showed that ectopic expression of miR-
• PMID 24357456

• Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.

• Vázquez S1, Lázaro M, Fírvida JL, Santomé L, Afonso J, Amenedo M, Casal J; Galician Lung Cancer Group (GGCP).Author information 1aMedical Oncology Service, Lucus Augusti University Hospital (HULA), Lugo bMedical Oncology Service, University Hospital of Vigo (CHUVI) cMedical Oncology Service, Povisa Hospital, Vigo dMedical Oncology Service, University Hospital Complex of Ourense (CHOU), Ourense eMedical Oncology Service, Arquitecto Marcide - Novoa Santos Hospital, Ferrol fMedical Oncology Service, Oncology Center of Galicia, A Coruña, Spain.AbstractAfter progression during first-line treatment in advanced non-small-cell lung cancer (NSCLC), a large percentage of patients are candidates for second-line treatment. The majority do not have epidermal growth factor receptor-activating mutations (EGFRwt). This article reviews the treatment options available for this subpopulation of patients, which includes essentially docetaxel, pemetrexed and erlotinib. These drugs all have similar efficacy, both in terms of objective response rates and overall survival, although with different toxicity profiles. In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking.
• Anti-cancer drugs.Anticancer Drugs.2014 Apr;25(4):368-74. doi: 10.1097/CAD.0000000000000066.
• After progression during first-line treatment in advanced non-small-cell lung cancer (NSCLC), a large percentage of patients are candidates for second-line treatment. The majority do not have epidermal growth factor receptor-activating mutations (EGFRwt). This article reviews the treatment options a
• PMID 24384805

Japanese Journal

• Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient

• Acta Medica Okayama 70(1), 63-65, 2016-02
• NAID 120005712608

• 導入化学放射線療法中の呼吸リハビリテーションは呼吸機能を改善させるか (特集 呼吸器・食道手術周術期における口腔ケアとリハビリテーションの現状) -- (呼吸リハビリテーション)

• 胸部外科 = The Japanese journal of thoracic surgery 69(1), 47-52, 2016-01
• NAID 40020697736

• 他肺葉の多発肺内リンパ節転移を認めた原発性肺癌の1例

• 肺癌 56(1), 38-42, 2016
• NAID 130005141784

---

★リンクテーブル★

リンク元	「NSC」「非小細胞」
拡張検索	「non-small-cell lung carcinoma」「non-small-cell cancer」
関連記事	「n」「small」「small cell」「cell」「non」

「NSC」

　　[★]

• 非小細胞

関

non-small cell

　

「非小細胞」

　　[★]

英

non-small cell、NSC

「non-small-cell lung carcinoma」

　　[★]

非小細胞肺癌、肺非小細胞癌、非小細胞性肺癌、非小細胞肺がん

関

non-small-cell lung cancer、nonsmall-cell lung cancer、nonsmall-cell lung carcinoma、NSCLC

「non-small-cell cancer」

　　[★]

非小細胞癌、非小細胞がん

関

nonsmall-cell cancer

「n」

　　[★]

• n.

• 例数

関

number of experiment、sample size

• pの前の[n]はmと記載する。synptom→symptom

「small」

　　[★]

• adj.

• 小さい

関

little、petit、tiny

　 　 　 　 　 　 　

「small cell」

　　[★]

• 小細胞

関

parvicellular、small-cell

「cell」

　　[★] 細胞 　 　 　 　 　 　 　

「non」

　　[★]

• comb form.

• 非

関

un